Conclusions :
Baseline AH levels of IL-6, IL-8, IP-10 and MCP-1 could be considered predictors of OCT-based DME response to DEX treatment. As a whole, our findings enforce clinical knowledge on DEX action on DME cases and could support future studies on treatment individualization of such a disease.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.